Early stage PC is driven primarily by AR signaling [110], and immunotherapeutic interventions targeting AR driven disease progression early may provide a more robust immune response prior to the development of an immunosuppressive TME during late stage PC. This evidence concerns the gene AR and pachyonychia congenita.